Skip to content Skip to footer
Subscribe Now

INSIGHTS+

Insights+ Key Biosimilars Events of February 2023
Insights+ Key Biosimilars Events of February 2023
Shots: Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of February, Alvotech entered into a commercialization agreement…
March 1, 2023
Insights+ Key Biosimilars Events of February 2023
Insights+: EMA Marketing Authorization of New Drugs in January 2023
Shots: The EMA approved 3 New Chemical Entity (NCE) and 5 Biologic Drugs in January 2023, leading to treatments for patients and advances in the healthcare industry In January 2023, the major highlights drugs were Xofluza’s Approval for influenza, Dupixent for eosinophilic esophagitis PharmaShots has compiled a list of a total of 8 new drugs…
February 23, 2023
Top Performing Drug of 2021 - Trulicity (February Edition)
Top Performing Drug of 2021 – Trulicity (February Edition)
Active Ingredient: dulaglutide Dosage Forms & Strengths:   Injection: 0.75 mg/0.5 mL, 1.5 mg/0.5 mL, 3 mg/0.5 mL, 4.5 mg/0.5 mL solution in a single-dose pen   Mechanism of Action: GLP-1 receptor agonist First Approval: US (Sep 18, 2014), EU (Nov 25, 2014)   Revenue Analysis1 Trulicity is used for the treatment of type 2 diabetes and to reduce the risk…
February 22, 2023
Insights+: The US FDA New Drug Approvals in January 2023
Insights+: The US FDA New Drug Approvals in January 2023
Shots: The US FDA approved 8 NDAs and 1 BLA in January 2023, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 9 novel products in 2023 In January 2023, the major highlights drugs were Rykindo (risperidone) approval for schizophrenia and bipolar 1 disorder, Brenzavvy (bexagliflozin) for type…
February 15, 2023
Disease of the Month: Age-Related Macular Degeneration
Disease of the Month: Age-Related Macular Degeneration
Introduction: AMD, an eye disease that can cause of loss of eyesight/blur vision mostly in people ≥50 years of age and it is the leading cause of visual impairment worldwide. It occurs when the part of the retina (macula) is damaged. Patients lose their central vision and cannot see fine details The three stages of…
February 9, 2023
Insights+ Key Biosimilars Events of January 2023
Insights+ Key Biosimilars Events of January 2023
Shots: Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of January, Celltrion reported P-III trial results of…
February 1, 2023
Top Performing Drug of 2021 – Imbruvica (January Edition)
Top Performing Drug of 2021 – Imbruvica (January Edition)
Active Ingredient: Ibrutinib   Dosage Forms & Strengths:   Capsules: 70 mg and 140 mg   Tablets: 140 mg, 280 mg, 420 mg, and 560 mg   Mechanism of Action: Bruton's tyrosine kinase Inhibitor (BTKi)  First Approval: US (13 Nov 2013), EU (Oct 2014)   Revenue Analysis Imbruvica is an oral therapy that inhibits a protein called Bruton's tyrosine kinase. Imbruvica was one…
January 25, 2023
Insights+: EMA Marketing Authorization of New Drugs in December 2022
Insights+: EMA Marketing Authorization of New Drugs in December 2022
Shots: The EMA approved 6 New Chemical Entity (NCE) and 6 Biologic Drugs in December 2022, leading to treatments for patients and advances in the healthcare industry In December 2022, the major highlights drugs were Pluvicto’s approval for progressive PSMA+ metastatic castration resistant prostate cancer, Dupixent for Prurigo Nodularis PharmaShots has compiled a list of…
January 24, 2023
Insights+: Key Takeaways of J.P. Morgan Healthcare Conference 2023 Based on Therapeutic Areas
Insights+: Key Takeaways of J.P. Morgan Healthcare Conference 2023 Based on Therapeutic Areas
Shots: The 41st Annual J.P. Morgan Healthcare Conference took place on 09 – 12 January 2023 in San Francisco, CA, USA. It is the largest and most informative healthcare investment symposium in the industry, bringing together a cohort of industry leaders, emerging fast-growing companies, innovative technology creators, and members of the investment community  The major announcement…
January 19, 2023
Insights+: The US FDA New Drug Approvals in December 2022
Insights+: The US FDA New Drug Approvals in December 2022
Shots: The US FDA approved 8 NDAs and 5 BLA in December 2022, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 86 novel products in 2022 In December 2022, the major highlights drugs were Krazati (adagrasib) approval for non-small cell lung cancer with a KRASG12C mutation, Sunlenca…
January 18, 2023
Load more